The effects of losartan and fosinopril diabetic patients in hypertensive type 2


Kavgaci H. , SAHIN A., ERSOZ O., EREM C. , OZDEMIR F.

DIABETES RESEARCH AND CLINICAL PRACTICE, cilt.58, ss.19-25, 2002 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 58 Konu: 1
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1016/s0168-8227(02)00102-x
  • Dergi Adı: DIABETES RESEARCH AND CLINICAL PRACTICE
  • Sayfa Sayıları: ss.19-25

Özet

The aim of this study is to evaluate the effects of losartan on blood pressure (BP), creatinine clearance (Ccr) and urinary albumin excretion (UAE), and to assess metabolic parameters in comparison with ACEL Thirty-three type 2 diabetic hypertensive patients were enrolled in the study. Twenty patients were randomized to receive 50 mg/day losartan and 13 patients to 10 mg/day fosinopril. Patients were studied at baseline and after 1 and 6 months. BP was significantly decreased in both groups at the end of the 1st and 6th month to a similar extent. Ccr had fallen in both groups at the end of 1st and 6th months. The effect of each drug on Ccr was similar (64.2 +/- 70.6 and 42.8 +/- 53.8 ml/min, respectively, NS). In the subgroup with microalbuminuria at baseline, UAE rate was lower in both groups at the end of the 1st and 6th months. However, when compared with the end of 1st month, the antiproteinuric effect of losartan was slightly decreased at the end of 6th month. Metabolic parameters did not change with either drug. Both drugs were well tolerated. Thus the antihypertensive effects of the two drugs were comparable. In conclusion, this study confirms the efficacy and safety of losartan as an antihypertensive drug in diabetic patients. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.